INC Research Appoints Head of Metabolic & Endocrine Diseases Clinical Division

Dr. David Subich to Lead New Therapeutic Area in Response to
Customer Demand
RALEIGH, N.C.--(Business Wire)--
INC Research (R), Inc., a therapeutically-focused contract
research organization (CRO) with a process for delivering reliable
results, today announced that David Subich, MD has been named the
senior director, Clinical Operations for Metabolic & Endocrine
Diseases. Based in Raleigh, he will be overseeing existing related
trials currently being conducted and developing comprehensive services
for this growing therapeutic area.

Dr. Subich has 23 years of experience as an attending physician
specializing in internal medicine with a focus on metabolic and
endocrine diseases. His rich background includes starting his own
practice group, North Central Ohio Clinic, Inc., serving as a
hospitalist, and a role as medical director covering several area
nursing homes. Since 1991, Dr. Subich was the principal investigator
on more than 50 clinical trials, where he was responsible for staff
and study oversight, patient exams and Good Clinical Practices (GCP)
at the research site.

He also served as an associate professor for Clinical Rotations
for The Ohio State University School of Medicine where he was
recognized for his teaching excellence. He has frequently presented on
scientific and educational panels on a range of treatment, practice
and clinical issues related to metabolic and endocrine diseases. Dr.
Subich was trained at The Cleveland Clinic Foundation after an
internship at Baylor College of Medicine in Houston. He received his
medical degree from The Medical College of Ohio.

"Dr. Subich has a unique combination of research experience and
hands-on medical practice in a variety of environments. He has
witnessed the rise of metabolic diseases as a physician and
understands the benefits of developing safe and effective drugs to
treat patients," said John Potthoff, COO of INC Research. "Our Trusted
Process methodology gives us the framework to efficiently expand into
new therapeutic areas as drug development trends emerge. We are
thrilled Dr. Subich has joined our team to establish our Metabolic &
Endocrine division."

"Diabetes and obesity are among the more prevalent metabolic
disorders, and we are seeing those greatly increase on a global
basis," said Dr. Subich. "I am excited to leverage the knowledge
inside of INC Research to build a world-class team to address the
unmet clinical needs for pharmaceutical and biotech companies
exploring current and future targets for metabolic and endocrine
diseases."

About INC Research(R) Inc.

INC Research is a therapeutically-focused contract research
organization with a high performance reputation for conducting global
clinical development programs of the highest integrity. Pharmaceutical
and biotechnology companies look to INC Research for a complete range
of customized Phase I through Phase IV programs in therapeutic areas
of specialty, and in innovative pediatric and women's health trials.
The company's "The Trusted Process(R)" methodology and therapeutic
foresight leads customers to more confident, better-informed drug and
device development decisions. INC Research is headquartered in
Raleigh, North Carolina, with 25 office locations and a presence in 32
countries worldwide. For more information please visit
www.incresearch.com.

INC Research
Kelly Foster, +1 619-224-1261
kellyefoster@earthlink.net

Copyright Business Wire 2008